Stephen Austin Fann, MD

Dr. Charles Greenberg practices medicine in the area of nonmalignant blood disorders. He provides consultative advice regarding the diagnosis and treatment of bleeding, thrombosis, and disorders of blood cells. Dr. Greenberg conducts translational research regarding new diagnostic tests for management of bleeding and thrombotic disorders. Working in collaborations within the MUSC health care system he assists in management of blood, blood products, and the cost-effective management on nonmalignant blood disorders. Clinical research on the use new approaches to manage bleeding and thrombosis continue as part of national and international groups targeting life-threatening blood disorders. Dr. Greenberg's basic research is in the area of transglutaminase structure and function and he has published in the area of Factor XIII and tissue transglutaminase biology related to hemostasis, thrombosis, wound healing, angiogenesis, and tumor growth.

Patrick Flume is a Distinguished Professor of Medicine and Pediatrics at the Medical University of South Carolina. He serves as the Powers-Huggins Endowed Chair for Cystic Fibrosis and oversees a large Cystic Fibrosis (CF) Center, including the largest adult CF program in South Carolina. He also leads large clinical programs dedicated to patients with bronchiectasis and non-tuberculous mycobacterial (NTM) infections. He is recognized by the national and international CF community having served on the CF Foundation Center Committee, the Adult Care Consensus Committee, and the Advisory Task Force on Adult Issues, the Professional Education Committee, the European CF Society’s Best Practices committee, and as founding co-chair of the CF Foundation’s Pulmonary Practice Guidelines Committee. He co-led the International Working Group on Antimicrobial Resistance in Cystic Fibrosis. He is the Editor-in-Chief for the Journal of Cystic Fibrosis. He serves as Associate Vice President for Clinical Research at MUSC, leads a very busy clinical research program for CF, bronchiectasis, and NTM, and is co-principal investigator for the South Carolina Clinical & Translational Research Institute. Many of these studies are related to new drug and therapy development for patients, but he also has an interest in determining optimal management of CF pulmonary exacerbations and is the co-PI in the STOP trials, aimed at identifying optimal treatments for exacerbations.

This provider is no longer seeing patients at MUSC Health.